I help biotech and pharma companies remove the friction points of outsourced R&D services with a technology platform
Ursheet P. from Mayfield Fund message to early founders: Don’t try to do it all on your own. You can get to scale faster, cheaper, and more efficiently through partnerships, collaborations, and outsourcing. Focus on your core capabilities and look externally to execute on scalability. #synbiobeta2024
In celebration of HFXI's fundiversary this month, New York Life Investments' Director of Product Management, Dan Petersen, highlights the key benefits of this highly-rated fund. Interested in learning more? Discover how you can help clients rebalance and diversify their equity portfolios with HFXI: https://bit.ly/46anVUi
In celebration of HFXI's fundiversary this month, New York Life Investments' Director of Product Management, Dan Petersen, highlights the key benefits of this highly-rated fund. Interested in learning more? Discover how you can help clients rebalance and diversify their equity portfolios with HFXI: https://bit.ly/46efBD3
In celebration of HFXI's fundiversary this month, New York Life Investments' Director of Product Management, Dan Petersen, highlights the key benefits of this highly-rated fund. Interested in learning more? Discover how you can help clients rebalance and diversify their equity portfolios with HFXI: https://bit.ly/3zAIBZi
Eager to learn more about how to effectively engage investors? Don't forget to register to our webinar this week to hear from industry experts on how to communicate value, build trust, and maintain long-term investor relationships. #LondonStockExchange #IssuerServices
Register to watch our Marketplace Webinar to hear Marketplace members Alex Stella (InvestorHub), Victoire de Pontbriand (Notified) and Gene Rubin (Rivel, Inc.) provide their expert insights on the best practices for effective investor engagement. The discussion will be chaired by James Devon (London Stock Exchange). 📆 Wednesday 11 September 2024 14:00 - 15:00 BST 🔗 Click here to register: https://lseg.group/3yD2Fdv #IssuerServices
🔍📈 In today's financial landscape, staying ahead means keeping a keen eye on market movers. Our latest analysis highlights the top 5 gainers and losers on the Canadian stock market, showcasing significant shifts and opportunities. From ME Therapeutics' impressive 135% surge to pivotal legal victories for Sandfire Resources, these developments offer valuable insights for investors and professionals alike. Join us in exploring these market dynamics and their potential impact on investment strategies. #Finance #StockMarket #Investing #CanadianMarketUpdate #ProfessionalInsights https://bit.ly/3uO0DoO
Epoch 9: What Downturn? Europe's VC Market Defies Gravity 👉Disciplined European valuations appear attractive 👉RIF Analysis - voluntary vs. involuntary 👉VC $$$'s starting to flow again? 👉Top Biotech Investor Rankings https://lnkd.in/dEkBy2bY
In celebration of HFXI's fundiversary this month, New York Life Investments' Director of Product Management, Dan Petersen, highlights the key benefits of this highly-rated fund. Interested in learning more? Discover how you can help clients rebalance and diversify their equity portfolios with HFXI: https://bit.ly/3WgtbT0
Exposure to innovative and transformative biotech companies has been a part of Pinnacle’s SMID investment strategy since our portfolio’s inception in 1996. Our latest white paper entitled “Biotechnology: Do Not Be Afraid” is authored by Kimon Passios, an Executive Vice President and a member of our Investment Team. Read more here - https://lnkd.in/ekrbH8-x #biotech #investments #investors #stocks #finance
#Liquidation preference clauses are often a critical and disputed part of negotiation in #funding agreements. Rudolf Gygax and Thomas Meier, Dr. discuss on Plattform Life Sciences the two basic types of “participating” and “non-participating” liquidation preferences and analyze whether distributions of #exit proceeds, particularly at low exit value, are balanced between #founders and #investors. You can find the link to the article in the comment field. Thanks to Viopas Venture Consulting GmbH
AVISTA & ASPEN FUNDS meeting: new ideas and important observations! We'd love if you are a listener of the our webinar, which is scheduled July 2 at 11:00am. Don't miss out on the chance to get valuable information and discover new opportunities to improve your wealth. Sign up for the webinar now! Link in the BIO. Aspen Funds Mike Sullivant Ben Fraser Nikita Volchek Igor Shaltanov
